GlassScriptPhysician profile
Kaylee Dawn Terrell
NPI 1801484936
$4,163.99
in general payments reported to CMS, 2019-2025
41 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $910 · 2023: $486 · 2024: $846 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.83 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,044.33 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $502.73 | 2021-2025 | |
| Boston Scientific Corporation | $281.68 | 2024-2025 | Bodyguardian, Watchman Access System, Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.30 | 2021-2023 | |
| Pfizer INC. | $224.69 | 2022-2025 | |
| Lilly USA, LLC | $185.87 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Novo Nordisk INC | $175.50 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $149.79 | 2023-2025 | Veozah |
| Amgen INC. | $136.67 | 2021-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $120.88 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $115.22 | 2025 | |
| Janssen Pharmaceuticals, INC | $80.91 | 2022 | |
| Corcept Therapeutics | $73.19 | 2025 | Korlym |
| Exact Sciences Corporation | $64.81 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $62.58 | 2022-2025 | Rexulti |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $61.32 | 2021-2024 | |
| Dexcom, INC. | $57.43 | 2021-2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $53.80 | 2024 | Apretude |
| Mylan Specialty L.P. | $43.68 | 2022-2023 | Yupelri |
| Baxter Healthcare | $40.99 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Xeris Pharmaceuticals, INC. | $40.01 | 2021-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $31.81 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Electromed, INC. | $31.06 | 2021 | |
| Inogen, INC. | $25.21 | 2022 | |
| Nestle Healthcare Nutrition INC. | $24.95 | 2022 | |
| Aimmune Therapeutics, INC. | $22.22 | 2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.57 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $21.21 | 2023 | Heplisav-B |
| Ipsen Biopharmaceuticals, INC | $19.36 | 2024 | Iqirvo |
| Advanced Respiratory, INC | $18.54 | 2021 | |
| Nabriva Therapeutics, Plc | $18.34 | 2022 | |
| Lundbeck LLC | $17.21 | 2025 | Rexulti |
| Insulet Corporation | $16.48 | 2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $15.00 | 2021 | |
| Inspire Medical Systems, INC. | $15.00 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $14.75 | 2025 | Auvelity |
| Eisai INC. | $14.59 | 2021 | |
| Abbott Laboratories | $14.21 | 2025 | Freestyle Libre 3 |
| Ethicon US, LLC | $12.98 | 2022 | |
| Esperion Therapeutics, INC. | $12.43 | 2021 | |
| Amarin Pharma, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylee Terrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.